Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05438342 |
TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis | 阶段
不适用
|
Date Added 2022-06-29 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Chemotherapy，checkpoint immunotherapy, targeted therapy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05611034 |
TitleIn Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | 阶段
第 1 阶段
|
Date Added 2022-11-09 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
oxaliplatin |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05479812 |
TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-07-29 |
地点
Arizona, United States
Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Pembrolizumab, WTX-124 |
标签
MSI-H/ MMRd
|
| NCT ID NCT05487235 |
TitleA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-08-04 |
地点
阿根廷
澳大利亚 巴西 加拿大 大韩民国 新西兰 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Atezolizumab, GDC-1971, Omeprazole |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05491317 |
TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2022-08-08 |
地点
法国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05493683 |
TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-08-09 |
地点
China,China,China,China,China,China
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Disitamab vedotin, Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04262687 |
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | 阶段
第二阶段
|
Date Added 2020-02-10 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT05205330 |
TitleCR6086 联合 Balstilimab 治疗 pMMR-MSS 转移性结直肠癌患者的 Ib/IIa 期研究 | 阶段
第二阶段
|
Date Added 2022-01-25 |
地点
意大利
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
AGEN2034, Balstilimab, CR6086 |
标签
MSS/ MMRp
|
| NCT ID NCT05201612 |
TitlePembrolizumab和Olaparib治疗同源重组缺陷（HRD）晚期结直肠癌（CRC）。 | 阶段
第二阶段
|
Date Added 2022-01-21 |
地点
西班牙
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
Unknown status
|
药物
Olaparib, Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03104439 |
TitleNivolumab 和 Ipilimumab 以及放疗治疗 MSS 和 MSI 高的结直肠癌和胰腺癌 | 阶段
第二阶段
|
Date Added 2017-04-07 |
地点
Massachusetts, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ipilimumab, Nivolumab, Opdivo, Yervoy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
